Bradley Sitko
About Bradley Sitko
Bradley Sitko is Chief Investment Officer of XOMA Royalty Corporation and was appointed as a non-executive director of LAVA Therapeutics (LVTX) effective November 13, 2025, following the tender offer closing. He holds a B.A. in History and Sociology of Science from the University of Pennsylvania and an M.B.A. from Columbia Business School; his LVTX board tenure began November 13, 2025 . At appointment, Sitko was not the beneficial owner of any LVTX shares, and he was designated to the LVTX board by the buyer (XOMA), indicating he is not independent from the buyer under the Dutch Corporate Governance Code .
Past Roles
| Organization | Role | Tenure | Committees / Impact |
|---|---|---|---|
| XOMA Royalty Corporation | Chief Investment Officer | Current (as disclosed) | Buyer-designated director at LVTX post-offer; strategic finance/investment oversight |
| RTW Investments, LP | Managing Director, Strategic Finance | Nov 2019 – Jan 2023 | Finance and investment strategy; served on RTW Investments ICAV board |
| Ji Xing Pharmaceuticals Limited | Chief Financial Officer | Dates not disclosed | CFO of RTW-incubated Shanghai-based biopharma |
| DNAnexus, Inc. | Vice President, Finance, Operations and Corporate Development | Mar 2015 – Nov 2019 | Finance and operations leadership at genetic data management firm |
| MTS Health Partners | Director | Oct 2008 – Mar 2015 | Investment banking; healthcare sector transactions |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| XOMA Royalty Corporation | Chief Investment Officer | Current | Officer of buyer acquiring LVTX; potential governance interlock |
| RTW Investments ICAV (Ireland) | Board Member | Dates not disclosed | Fund governance role |
Board Governance
- Appointment and Independence: Sitko was appointed as a non-executive director effective November 13, 2025; he is buyer-designated and therefore not independent from the buyer under the LVTX governance framework, which identifies Kapil Dhingra and Karen J. Wilson as Independent Directors for minority protections .
- Committee assignments: Not disclosed post-closing; prior (pre-offer) committee composition is superseded by board changes .
| EGM Voting Outcome (Nov 7, 2025) | Votes For | Votes Against | Abstain |
|---|---|---|---|
| Bradley Sitko – Non-Executive Director | 16,647,337 | 11,320 | 34,544 |
- Board Composition Post-Closing: Six directors – Buyer designees Owen Hughes (executive), Thomas Burns, Bradley Sitko, Maricel Montano (non-executive), and continuing independent directors Kapil Dhingra and Karen J. Wilson .
- Minority protections: Actions that could dilute non-tendering shareholders or unequally treat them require affirmative vote of Independent Directors (Dhingra, Wilson) .
Fixed Compensation
- Not disclosed for Sitko as a newly appointed LVTX non-executive director; the November 13, 2025 8-K contains no director compensation details for buyer designees .
Performance Compensation
- Not disclosed for Sitko (no LVTX director equity/PSU/option awards reported in LVTX filings as of appointment) .
Other Directorships & Interlocks
| Company | Role | Committee/Chair | Interlock/Conflict Notes |
|---|---|---|---|
| LVTX | Non-Executive Director | Not disclosed | Buyer-designated director; officer of buyer (XOMA) |
| XOMA Royalty Corporation | Chief Investment Officer | N/A | Officer of LVTX’s buyer; governance interlock with LVTX board |
Expertise & Qualifications
- Finance and investment leadership across biopharma royalty aggregation, strategic finance, and CFO roles; prior investment banking experience at MTS Health Partners .
- Education: B.A., University of Pennsylvania; M.B.A., Columbia Business School .
Equity Ownership
| Item | Amount / Status |
|---|---|
| LVTX beneficial ownership at appointment (Nov 13, 2025) | 0 Shares; “not the beneficial owner of any Shares” |
| Hedging/Pledging policy | LVTX prohibits hedging and pledging by directors, officers, and employees |
Insider Trades
| Issuer | Form | Date | Summary |
|---|---|---|---|
| LVTX | None found | Through Nov 13, 2025 | At appointment, Sitko held no LVTX beneficial ownership; no LVTX Form 4 filings identified |
| XOMA Royalty Corp (XOMA) | Form 4 | Jan 10, 2025 | Officer transactions filed (details in EDGAR) |
| XOMA Royalty Corp (XOMA) | Form 4 | Mar 25, 2025 | Officer transactions filed |
| XOMA Royalty Corp (XOMA) | Form 4 | Apr 2, 2025 | Officer transactions filed |
| XOMA Royalty Corp (XOMA) | Form 4 | Apr 9, 2025 | Officer transactions filed |
| XOMA Royalty Corp (XOMA) | Form 4 | Jun 30, 2025 | Non-derivative/ESPP-related purchases reported; signed by attorney-in-fact |
| XOMA Royalty Corp (XOMA) | Form 4 | Sep 19, 2025 | Performance Stock Units reported; Form 4 filed |
Governance Assessment
- Strengths: Clear disclosure of buyer-designated appointments and minority protections via Independent Directors (Dhingra, Wilson) needing to approve dilutive or unequal actions; strong shareholder support in EGM voting for Sitko’s appointment .
- Alignment: At appointment, Sitko held no LVTX shares; LVTX’s hedging/pledging ban supports alignment, though actual LVTX equity holding is nil as of appointment .
- Conflicts/RED FLAGS:
- Buyer interlock: Sitko is CIO of XOMA, the acquirer; this is a potential conflict regarding fiduciary duties to LVTX’s minority shareholders. LVTX mitigated with Independent Director veto rights on key actions .
- Committee transparency: Post-closing committee assignments (Audit, Compensation, Nominating) not disclosed yet, limiting visibility into oversight roles and effectiveness .
- Engagement/Attendance: No attendance record yet for Sitko at LVTX board/committee meetings (appointment on Nov 13, 2025) .
Implication for investors: Sitko’s buyer-officer status warrants close monitoring of related-party dealings and post-closing committee composition; the Independent Directors’ affirmative vote requirements are a material safeguard for minority holders during the post-offer reorganization . Strong EGM support reduces governance uncertainty, but lack of disclosed director compensation/committee roles limits assessment of incentives and oversight rigor .